Verik Is Committed To Creating The Best
Curative Treatment Options For Advanced Cancer

Curative by Design™

Our mission is to apply the best know-how, science, technology and innovation to achieve the full curative potential of Adoptive (T) Cell Therapy (ACT).

We believe that achieving this goal starts with a High Curative Potential (HCP) target; however, successful delivery takes a combination of the right modality, focused application, use of technology, perspective, and innovation.

  • Specificity Supports Broad Adoption more

    The potential for on-target and off-target toxicity is addressed upfront in Verik's SeleCTR platform. Targets are stringently cancer-specific and their High Probability epitopes are subject to a final algorithm screen for neoantigen specificity before a peptide sequence is cleared for use in TCR selection.

     

 

© 2017 Verik Bio, Inc
website design by Alice Sargent